[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336136-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-336136-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","second-malignant-neoplasms-within-5-years-from-first-primary-diagnosis-in-pediatric-oncology-patients-in-canada-a-population-based-retrospective-cohort-study","Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada - a population-based retrospective cohort study","","Assessing early second malignant neoplasms (SMN) in children, this study evaluates incidence, clinical characteristics, management approaches, and outcomes for pediatric oncology patients who develop a second malignancy within 5 years after their first primary diagnosis. Using the Cancer in Young People – Canada (CYP-C) national registry, investigators conducted a retrospective cohort analysis of patients diagnosed with their first cancer between 2000 and 2015. Among 20,272 children, 0.7% developed SMN within 5 years; SMN cases showed reduced survival and the analysis highlights potential risk factors including epipodophyllotoxins, radiation exposure, and hematopoietic stem cell transplantation.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/second-malignant-neoplasms-within-5-years-from-first-primary-diagnosis-in-pediatric-oncology-patients-in-canada-a-population-based-retrospective-cohort-study/336136/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/second-malignant-neoplasms-within-5-years-from-first-primary-diagnosis-in-pediatric-oncology-patients-in-canada-a-population-based-retrospective-cohort-study/336136.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What time window defines early second malignant neoplasms in this study?","Question",{"text":63,"@type":64},"Early SMN refers to second malignant neoplasms developing within 5 years from the first primary cancer diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study cohort identified and what registry was used?",{"text":68,"@type":64},"A retrospective cohort study used the Cancer in Young People – Canada (CYP-C) national pediatric cancer registry to review patients diagnosed with their first cancer from 2000 to 2015.",{"name":70,"@type":61,"acceptedAnswer":71},"What proportion of pediatric patients developed a SMN within 5 years, and how did it affect survival?",{"text":72,"@type":64},"Of 20,272 children with a first malignancy, 0.7% were diagnosed with SMN within 5 years. The SMN cohort had an inferior three-year survival rate (79.1%) compared with the non-SMN cohort (89.7%).",{"name":74,"@type":61,"acceptedAnswer":75},"Which risk factors are highlighted for early SMN in the results?",{"text":76,"@type":64},"The study identifies several possible risk factors, including use of epipodophyllotoxins, exposure to radiation, and hematopoietic stem cell transplantation.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},336136,1790192929,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 28 March 2024  \nDOI 10.3389/fonc.2024.1376652  \nOPEN ACCESS  \nEDITED BY  \nParaskevi Panagopoulou,  \nAristotle University of Thessaloniki, Greece  \nREVIEWED BY  \nHelen Kosmidis, Mitera Hospital, Greece Lars Hjorth,  \nSkåne University Hospital, Sweden  \n*CORRESPONDENCE Kate Lim  \n [kate.lim@dal.ca](kate.lim@dal.ca)[ ](kate.lim@dal.ca)Ketan Kulkarni  \n [Ketan.Kulkarni@iwk.nshealth.ca](Ketan.Kulkarni@iwk.nshealth.ca)[ ](Ketan.Kulkarni@iwk.nshealth.ca)†These authors share ﬁrst authorship  \nRECEIVED 25 January 2024  \nACCEPTED 11 March 2024  \nPUBLISHED 28 March 2024  \nCITATION  \nRicci C, Subburaj D, Lim K, Shukla N, Kaur J, Xie L, Laverty M, Zakaria D, Pole J, Pelland-Marcotte M-C, Barber R, Israels SJ, Tran T-H, Oberoi S, Renzi S, MacDonald T, Sung L and Kulkarni K (2024) Second malignant neoplasms within 5 years  \nfrom ﬁrst primary diagnosis in pediatric oncology patients in Canada: a populationbased retrospective cohort study.  \nFront. Oncol. 14:1376652 .  \ndoi: 10.3389/fonc.2024.1376652  \nCOPYRIGHT  \n© 2024 Ricci, Subburaj, Lim, Shukla, Kaur, Xie, Laverty, Zakaria, Pole, Pelland-Marcotte, Barber, Israels, Tran, Oberoi, Renzi, MacDonald, Sung and Kulkarni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nSecond malignant neoplasms within 5 years from ﬁrst primary diagnosis in pediatric oncology patients in Canada: a populationbased retrospective cohort study  \nChristina Ricci 1†, Divya Subburaj 2†, Kate Lim 3*†, Neetu Shukla 1, Jaskiran Kaur 4, Lin Xie 1, Meghan Laverty 1, Dianne Zakaria 1, Jason Pole 5,6, Marie-Claude Pelland-Marcotte 7,8,  \nRandy Barber 9, Sara J. Israels 10, Thai-Hoa Tran 11,12,  \nSapna Oberoi 10,13, Samuele Renzi 14,15, Tamara MacDonald 16,17, Lillian Sung 14,18 and Ketan Kulkarni 2*  \n1 Lifespan Chronic Disease and Conditions Division, Public Health Agency of Canada, Ottawa,  \nON, Canada, 2 Department of Pediatrics, Division of Hematology-Oncology, Izzak Walton Killam (IWK) Health Centre, Halifax, NS, Canada, 3 Faculty of Medicine, Dalhousie University, Halifax, NS, Canada,  \n4Surveillance Systems and Data Management Division, Public Health Agency of Canada, Ottawa, ON, Canada, 5 Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada,  \n6Centre for Health Sciences Research, University of Queensland, Brisbane, QLD, Australia, 7 Division of Pediatric Hematology-Oncology, CHU de Que´ bec-Centre Mère-Enfant Soleil, Quebec City, QC, Canada, 8 Research Centre of the CHU de Que´ bec, Axe Reproduction, Sante´ de la Mère et del ’ Enfant, Quebec City, QC, Canada, 9C17 Research Network, C17 Council, Edmonton, AB, Canada, 10 Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada, 11 Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montre´al, QC, Canada, 12 Immune Diseases and Cancers Axis, CHU Sainte-Justine Research Center, Montre´al, QC, Canada,  \n13 Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, MB, Canada, 14 Division of Hematology Oncology, The Hospital for Sick Children, Toronto, ON, Canada,  \n15 Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientiﬁc Institute, Milan, Italy, 16 Department of Pharmacy, Izzak Walton Killam (IWK) Health, Halifax, NS, Canada, 17 Faculty of Health Professions, Dalhousie University, Halifax, NS, Canada, 18Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada  \nIntroduction: From the advancement of trea","cbCainJuRcGhBlo1","https://ap.wps.com/l/cbCainJuRcGhBlo1","pdf",1491776,14,"English","# Introduction\n## Study objective and background\n# Method\n## Data source and cohort definition\n# Results\n## Incidence and survival impact\n## Identified risk factors\n# Discussion\n## National scope and implications\n# Keywords","[{\"question\":\"What time window defines early second malignant neoplasms in this study?\",\"answer\":\"Early SMN refers to second malignant neoplasms developing within 5 years from the first primary cancer diagnosis.\"},{\"question\":\"How was the study cohort identified and what registry was used?\",\"answer\":\"A retrospective cohort study used the Cancer in Young People – Canada (CYP-C) national pediatric cancer registry to review patients diagnosed with their first cancer from 2000 to 2015.\"},{\"question\":\"What proportion of pediatric patients developed a SMN within 5 years, and how did it affect survival?\",\"answer\":\"Of 20,272 children with a first malignancy, 0.7% were diagnosed with SMN within 5 years. The SMN cohort had an inferior three-year survival rate (79.1%) compared with the non-SMN cohort (89.7%).\"},{\"question\":\"Which risk factors are highlighted for early SMN in the results?\",\"answer\":\"The study identifies several possible risk factors, including use of epipodophyllotoxins, exposure to radiation, and hematopoietic stem cell transplantation.\"}]","Second malignant neoplasms within 5 years from first primary diagnosis in pediatric oncology patients in Canada - a population-based retrospective cohort study | PDF",1790013767,35]